Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCAR02 in Relapsed/Refractory B-cell Lymphoma
NCT07211048Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Mar 2026
- Primary completion
- Dec 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of ciltacabtagene autoleucel in B cell lymphoma, sponsored by The First Affiliated Hospital of USTC. Primary endpoints: Adverse events at 1 year and Persistence, accumulation, and migration of anti-CD19 gene injection at 1 year. Started Mar 2026; status: recruiting.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT07211048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07211048.